currently employ close to 500 people across both offshore and onshore locations. The company operates a wide range of work and survey ROVs from its fleet of To subscribe to Press releases from this ...

to provide outstanding solutions for healthcare professionals globally. The Company is headquartered in Oslo, Norway. Further information is available at www.observemedical.com. This information is ...

231,156,736 shares, each with a par value of NOK 1.00. All the exercised options have been granted in accordance with the Company's To subscribe to Press releases from this issuer, visit the ...

representing 85% of Convatec's 2021 market for the product. · Global Reach: Orders received from 27 countries, with 16 countries placing multiple/repeat orders. For the whole UnoMeter portfolio, the ...

will commence on 16 June 2025 or as soon as possible after that date. The purpose of the buy-backs is to maintain an efficient capital structure and improve shareholder returns. The programme will ...

Paris, France – June 12, 2025 – Eviden, the Atos Group product brand leading in advanced computing, cybersecurity products, mission-critical systems and vision AI today announces the availability of a ...

1,539 New Shares in the Company at a price per New Share of NOK 5.31681. monitoring of various body analytes. Lifecare's focus is to bring the next generation of Continuous Glucose Monitoring ("CGM") ...

Orange intends to issue a new series of Euro-denominated hybrid notes and to launch a tender offer on some of its outstanding hybrid notes Orange S.A. (the Company) is today announcing its intention ...

issue amount of USD 200,000,000 and ISIN NO0013063495 on Euronext Oslo Børs. To subscribe to Press releases from this issuer, visit the Subscription to Company news section in your account section or ...

improvements across all the three business areas Sea Based, Land Based and Digital in the years to come. -Our products, technologies and solutions can help improve fish health and welfare, enable new ...

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, ...

a full year ahead of plan. The company also reported a 50% year-over-year improvement in its adjusted EBIT margin for the quarter, which rose to 14.1%, ...